Revenue
$94.2B
▲ 6.0% YoY
Net Income
$26.8B
▲ 90.6% YoY
EPS
$11.03
▲ 90.5% YoY
Cash
$19.7B
▼ 18.2% YoY
FY 2025 · As of 2025-12-28
Last 90 days
| Insider | Type | Date | Shares | Price | Value | |
|---|---|---|---|---|---|---|
Wengel Kathryn E EVP, Chief TO and Risk Officer | Vest | Jun 11, 2026 | 10.0K | $115.67 | $1.16M | Form 4 ↗ |
Wengel Kathryn E EVP, Chief TO and Risk Officer | Sell | Jun 11, 2026 | 10.0K | $241.15 | $2.41M | Form 4 ↗ |
REED JOHN C EVP, Innovative Medicine, R&D | Vest | May 1, 2026 | 25.3K | $0.00 | $0 | Form 4 ↗ |
REED JOHN C EVP, Innovative Medicine, R&D | Sell tax | May 1, 2026 | 11.0K | $229.85 | $2.53M | Form 4 ↗ |